Wells Fargo
OCUL icon

Wells Fargo’s Ocular Therapeutix OCUL Stock Holding History

Wells Fargo’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33,600
Closed -$551K – 7277
2021
Q1 		$551K Buy
+33,600
New +$647K ﹤0.01% 4634

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo's OCUL Position: Q2 2026 in Review

Wells Fargo increased its Ocular Therapeutix (OCUL) stake by 105% in Q2 2026, buying an estimated $1.07M and bringing the position to 231,073 shares worth $2.27M. The position accounts for ﹤0.01% of the portfolio, ranked #3489.

Wells Fargo first reported a position in OCUL in Q4 2014 and has held it in 47 quarters since. The position peaked at $8.79M in Q1 2021. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Wells Fargo held 231,073 shares of Ocular Therapeutix worth $2.27M as of Q2 2026.
  • Wells Fargo bought 118,307 Ocular Therapeutix shares in Q2 2026, an estimated $1.07M.
  • Ocular Therapeutix made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3489 holding.
  • Wells Fargo first reported a position in Ocular Therapeutix in Q4 2014 and has held it in 47 quarters since.
  • Wells Fargo's Ocular Therapeutix position peaked at $8.79M in Q1 2021.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.